Participating Faculty

Supplements and Featured Publications, Health Economic Perspectives in Fibromyalgia: Focus on Pregabalin, Volume 16, Issue 5

Health Economic Perspectives in Fibromyalgia: Focus on Pregabalin

This supplement to The American Journal of Managed Care discusses current evidence and strategies to improve clinical and economic outcomes associated with fibromyalgia treatment.

Faculty

Jose Alvir, DrPH

Senior Director

Pfizer, Inc.

New York, NY

Lesley Arnold, MD

Professor of Psychiatry

University of Cincinnati College of Medicine

Cincinnati, OH

Gary Bazalo, MS, MBA

Partner

Managed Solutions, LLC

Conifer, CO

Ariel Berger, MPH

Senior Analyst

Policy Analysis Inc

Brookline, MA

William J. Cardarelli, PharmD

Director of Pharmacy

Harvard Vanguard Medical Associates

Watertown, MA

Arthi Chandran, MPH

Associate Director

Market Access-Global Health Economics and Outcomes Research

Pfizer, Inc.

New York, NY

Daniel Clauw, MD

Professor and Director

Chronic Pain and Fatigue Research Center

Department of Anesthesiology

University of Michigan

Ann Arbor, MI

Michael Deminski, MS, RPh

Senior Director, Medical Affairs

Pfizer, Inc

New York, NY

Ellen M. Dukes, PhD

Senior Director

Pfizer, Inc.

New York, NY

John Edelsberg, MD, MPH

Medical Director

Policy Analysis Inc

Brookline, MA

Mugdha Gore, PhD, BPharm

Principal Consultant

Avalon Health Solutions, Inc.

Philadelphia, PA

John Hanna, MBA

Director, Health Services Research

Humana Inc

Health Services Research Center

Miami, FL

Ashish V. Joshi, PhD

Associate Director

Pfizer, Inc.

New York, NY

Hua Li, MD, PhD

Biostatistician (Scientist)

Humana Inc

Miami, FL

Philip Mease, MD

Seattle Rheumatology Associates

Director, Division of Rheumatology Research

Swedish Medical Center

Clinical Professor

University of Washington School of Medicine

Seattle, WA

Gerry Oster, PhD

Vice President

Policy Analysis Inc

Brookline, MA

Ana Palacio, MD, MPH

Assistant Professor

Department of Medicine

University of Miami

Miami, FL

Alesia Sadosky, PhD, MPH, MBA

Director

Pfizer, Inc.

New York, NY

Robert Sanchez, RPh, MS, PhDc

Director

US Health Economics and Outcomes Research

Pfizer, Inc.

New York, NY

Stuart Silverman, MD

Clinical Professor of Medicine and Rheumatology

UCLA/Cedars-Sinai Medical Center and OMC Clinical Research Center

Los Angeles, CA

Claudia L. Uribe, MD, MHA

Manager, Health Services Research

Humana Inc

Miami, FL

Richard C. Weiss, MS

Partner

Managed Solutions, LLC

Mt. Freedom, NJ

Gergana Zlateva, PhD

Senior Director

Global Market Access Lead

Lyrica Primary Care Business Unit

Pfizer, Inc.

New York, NY

Faculty Disclosures

These participants report relationships with the following organizations:

Jose Alvir, DrPH

Employee/stockholder: Pfizer, Inc.

Lesley Arnold, MD

Consultant:

Allergan, AstraZeneca, Boehringer Ingelheim, Cypress Bioscience, Forest, Lilly, Pfizer, Inc., sanofi-aventis, Takeda, Theravance, UCB, Wyeth Pharmaceuticals

Grant/research support:

Allergan, Boehringer Ingelheim, Cypress Bioscience, Forest, Lilly, Pfizer, Inc., Wyeth Pharmaceuticals

Speakers' bureau:

Forest

Gary Bazalo, MS, MBA

Receipt of payment for the conduct of the study and article development

Ariel Berger, MPH

Employee of Policy Analysis Inc, which received financial support from Pfizer, Inc. for the conduct of this analysis and article development

Arthi Chandran, MPH

Employee/stockholder:

Pfizer, Inc.

Daniel Clauw, MD

Consultant:

AstraZeneca, Cypress Bioscience, Forest, Lilly, Pfizer, Inc., Pierre Fabre, UCB

Grant/research support:

Forest, Pfizer, Inc.

Michael Deminski, MS, RPh

Employee/stockholder: Pfizer, Inc.

Ellen M. Dukes, PhD

Employee/stockholder: Pfizer, Inc.

John Edelsberg, MD, MPH

Employee of Policy Analysis Inc, which received financial support from Pfizer, Inc. for the conduct of this analysis and article development

Mugdha Gore, PhD, BPharm

Employee of Policy Analysis Inc, which received financial support from Pfizer, Inc. for the conduct of this analysis and article development

Stockholder:

Pfizer, Inc.

John Hanna, MBA

Consultant to Pfizer, Inc. during the conduct of this study and article development

Ashish V. Joshi, PhD

Employee/stockholder: Pfizer, Inc.

Hua Li, MD, PhD

Consultant to Pfizer, Inc. during the conduct of this study and article development

Philip Mease, MD

Consultant/grant recipient:

Allergan, Boehringer Ingelheim, Cypress Bioscience, Forest, Fralex, Lilly, Pfizer, Inc.

Honoraria/speakers' bureau:

Cypress Bioscience, Forest, Lilly, Pfizer, Inc.

Gerry Oster, PhD

Employee of Policy Analysis Inc, which received financial support from Pfizer, Inc. for the conduct of this analysis and article development

Ana Palacio, MD, MPH

Consultant to Pfizer, Inc. during the conduct of this study and article development

Alesia Sadosky, PhD, MPH, MBA

Employee/stockholder: Pfizer, Inc.

Robert Sanchez, RPh, MS

Employee/stockholder: Pfizer, Inc.

Stuart Silverman, MD

Consultant/advisory board member:

Lilly, Pfizer, Inc.

Grants:

Lilly, Pfizer, Inc.

Lecture fees:

Lilly, Pfizer, Inc.

Claudia L. Uribe, MD, MHA

Consultant to Pfizer, Inc. during the conduct of this study and article development

Richard C. Weiss, MS

Receipt of payment for the conduct of the study and article development

Gergana Zlateva, PhD

Employee/stockholder: Pfizer, Inc.

William J. Cardarelli, PharmD, has nothing to disclose relative to the topic of this supplement.

This supplement was funded by Pfizer, Inc.

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.